Telix Pharms
Price
Price
Frequently asked questions
What is Telix Pharms's market capitalization?
What is Telix Pharms's Price-to-Earnings (P/E) ratio?
What is the Earnings Per Share (EPS) for Telix Pharms?
What are the analyst ratings and target price for Telix Pharms's stock?
What is Telix Pharms's revenue over the trailing twelve months?
What is the EBITDA for Telix Pharms?
What is the free cash flow of Telix Pharms?
What is the 5-year beta of Telix Pharms's stock?
How many employees does Telix Pharms have, and what sector and industry does it belong to?
What is the free float of Telix Pharms's shares?
Financials
Market Cap
$4.91B5Y beta
2.26EPS (TTM)
$0.0972Free Float
196.01MP/E ratio (TTM)
150.84Revenue (TTM)
$419.14MEBITDA (TTM)
$52.53MFree Cashflow (TTM)
$13.83MPricing
Analyst Ratings
The price target is $12.26 and the stock is covered by 8 analysts.
Buy
8
Hold
0
Sell
0
Information
Telix Pharmaceuticals Limited is an Australia-based is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. It develops a portfolio of clinical and commercial stage products that addresses significant unmet medical needs in oncology and rare diseases. It operates a pipeline of theranostic radiopharmaceutical product candidates with a focus in urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. It operates under four business units: Therapeutics, Precision Medicine (Diagnostics), Lightpoint (Medtech), and Telix Manufacturing Solutions (TMS). Its lead imaging product is gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix). Its other pipelines include TLX591, TLX592, TLX250, TLX250-CDx, TLX101, TLX101-CDx, TLX300, TLX300-CDx, TLX66, and TLX66-CDx.
234
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker